In Allergy, asthma & immunology research
The prevalence of allergic rhinitis (AR) and the socioeconomic burden associated with the medical cost and quality of life (QOL) of AR have progressively increased. Therefore, practical guidelines for the appropriate management of AR need to be developed based on scientific evidence while considering the real-world environment, values, and preferences of patients and physicians. The Korean Academy of Asthma, Allergy and Clinical Immunology revised clinical guidelines of AR to address key clinical questions of the management of AR. Part 1 of the revised guideline covers the pharmacological management of patients with AR in Korea. Through a meta-analysis and systematic review, we made 4 recommendations for AR pharmacotherapy, including intranasal corticosteroid (INCS)/intranasal antihistamine (INAH) combination therapy, oral antihistamine/INCS combination therapy, leukotriene receptor antagonist treatment in AR patients with asthma, and prophylactic treatment for patients with pollen-induced AR. However, all recommendations are conditional because of the low or very low evidence of certainty. Well-designed and strictly executed randomized controlled trials are needed to measure and report appropriate outcomes.
Yang Song-I, Lee Il Hwan, Kim Minji, Ryu Gwanghui, Kang Sung-Yoon, Kim Mi-Ae, Lee Sang Min, Kim Hyun-Jung, Park Do-Yang, Lee Yong Ju, Kim Dong-Kyu, Kim Soo Whan, Kim Do Hyun, Jun Young Joon, Park Sang Chul, Kim Bong-Seong, Chung Soo Jie, Lee Hyun Jong, Kim Hyo-Bin, Choi Jeong-Hee, Choi Gil-Soon, Yang Hyeon-Jong
2023-Jan
Rhinitis, allergic, asthma, drug therapy, guideline
